View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 12, 2020

Emergent BioSolutions to develop two Covid-19 therapies

Emergent BioSolutions has begun efforts to develop two plasma-derived product candidates to treat and prevent the new Covid-19 coronavirus infection.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Emergent BioSolutions has begun efforts to develop two plasma-derived product candidates to treat and prevent the new Covid-19 coronavirus infection.

The products will build on the company’s hyperimmune platforms.

Emergent notes that hyperimmunes are polyclonal antibodies obtained from plasma. These therapeutics use the immune response to deliver protection from infection.

The company will develop COVID-HIG, produced from human plasma with antibodies to SARS-CoV-2, to potentially treat severe infection in hospitalised patients, and also to protect at-risk individuals.

COVID-EIG will be generated using plasma of immunised horses with antibodies to SARS-CoV-2, for the potential treatment of severe hospitalised patients.

Emergent BioSolutions senior vice-president and therapeutics business unit head Laura Saward said: “Emergent is advancing these programs based on our hyperimmune platforms and using existing infrastructure and capabilities that we deployed for our recently completed Phase II clinical trial for our influenza hyperimmune FLU-IGIV to treat patients hospitalized with Influenza A.

“By leveraging our platform and capabilities that are already in place, Emergent is in a state of readiness to develop treatment options for Covid-19 to potentially protect healthcare workers and others on the frontline, as well as treat individuals who have fallen ill.”

The company has already started plasma collection for human and equine platforms. It aims to manufacture clinical material within the coming four to five months and expects to start a clinical study in the third quarter of this year.

The company’s hyperimmune plasma product manufacturing platform was previously used to develop antibody therapeutics for Vaccinia Immune Globulin Intravenous, smallpox vaccine complications and anthrax treatment.

In a separate development, Emergent BioSolutions signed an agreement with Novavax to provide contract development and manufacturing (CDMO) services for the latter’s Covid-19 experimental vaccine candidate.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology